ClinicalTrials.gg
Sign In

Triple Negative Breast Neoplasms clinical trials

The registry lists 1,219 studies for Triple Negative Breast Neoplasms across more than 10 countries. 445 are recruiting or about to start. 857 of them are mainly about Triple Negative Breast Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

ClinicalTrials.gov finds 1,517 studies for Triple Negative Breast Neoplasms. How that becomes 1,219 here

This page counts the studies the registry files under Triple Negative Breast Neoplasms, and those it files under no condition that list Triple Negative Breast Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,517Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −8List Triple Negative Breast Neoplasms as a condition, but the registry did not file them under itMost often written as “Advanced Triple Negative Breast Cancer” (2), “Triple Negative Breast Cancer Patients” (1), and “Advanced, Androgen Receptor Positive Triple Negative Breast Cancer” (1). The registry filed them under other conditions only, most often Breast Neoplasms (4) and Carcinoma, Non-Small-Cell Lung (1).
  3. −290Match it another way201 name it in the title and 89 by a synonym or other text the search reads.
  4. 1,219The count on this page17 of them list Triple Negative Breast Neoplasms in their own words; the registry filed them under no condition.

Get an email when these change. Save the Triple Negative Breast Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Recruiting
331
Completed
303
Active, not recruiting
157
Terminated
154
Not yet recruiting
109
Status unknown
91

Phase

Phase 2
616
Phase 1
466
Phase 3
101
Early Phase 1
28
Phase 4
6

Where

United States
645
China
252
Spain
136
France
125
Canada
96
Italy
94

Who runs them

Fudan University (65) · National Cancer Institute (NCI) (45) · M.D. Anderson Cancer Center (29) · Novartis Pharmaceuticals (22) · AstraZeneca (14) · Merck Sharp & Dohme LLC (14) · City of Hope Medical Center (11) · Pfizer (11)

What is being tested here

Drugs under test in Triple Negative Breast Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Pembrolizumab17749
Paclitaxel16861
Carboplatin16955
Sacituzumab govitecan11621
Cyclophosphamide10526
Camrelizumab10620
Sacituzumab tirumotecan8511
Capecitabine7418
Trastuzumab rezetecan747
Olaparib6118

Drug classes tested here Immune checkpoint inhibitors 78 open · Antimitotic agents 27 open · Antibody-drug conjugates (ADCs) 26 open · Tyrosine kinase inhibitors (TKIs) 16 open · PARP inhibitors 14 open

Coming up

60phase 3 studies under way
185studies finish main data collection within a year10 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 331 Triple Negative Breast Neoplasms studies recruiting now, 231 (70%) set no upper age limit and 85 (26%) stop at 75 or younger. 12 (4%) take children under 18. 106 (32%) are for women only and 0 (0%) for men only; 6 (2%) take healthy volunteers.

Recruiting studies that take each age, of 331
AgeWomenMen
106 (2%)5 (2%)
18322 (97%)218 (66%)
30328 (99%)223 (67%)
40330 (100%)224 (68%)
50330 (100%)224 (68%)
65329 (99%)223 (67%)
75283 (85%)213 (64%)
85240 (73%)192 (58%)

Across all 1,219 studies, recruiting or not: 19% stop at 75 or younger and 2% at 65; 2% take children; 37% are for women only and <1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Triple Negative Breast Neoplasms studies take

Of 255 phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 59 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 154 mo35–80 · 208 studies53 mo32–70 · 135 studies58 mo37–96 · 73 studies
Phase 1/256 mo43–79 · 118 studies54 mo44–77 · 70 studies—
Phase 259 mo37–94 · 255 studies—60 mo38–99 · 220 studies
Phase 365 mo39–103 · 60 studies——
Interventional, no phase82 mo36–… · 49 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 14, 2026.

Started recruiting4

Results posted4

Newly registered8

Show 3 more

Studies

Recruiting first, then most recently updated. Showing 50 of 1,219. Browse all 1,219 → or search them.